biostudies-literaturePetrylak DPNCATS NIH HHSBayer HealthCare100082https://www.ebi.ac.uk/biostudies/studies/S-EPMC7985394biostudies-literatureUnknown6(2)<h4>Background</h4>In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide).<h4>Patients and methods</h4>This randomized, non-comparative phase IIa three-arm trial (NCT02034552) evaluated technetium-99m-based BSLA response rate (RR), safety, radiologic progression-free survival (rPFS), and time to first symptomatic skeletal event (SSE) in men with mCRPC and bone metastases receiving radium-223 with/without abiraterone/prednisone or enzaluESMO openA randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.PMC7985394UL1 TR001863Trandafir LPetrylak DPMehlhaff BAQuinn DIDawson NAAlbany CSiegel JVaishampayan UNPatel KRHigano CSWagner VJNordquist LTSartor OfalseA randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.<h4>Background</h4>In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide).<h4>Patients and methods</h4>This randomized, non-comparative phase IIa three-arm trial (NCT02034552) evaluated technetium-99m-based BSLA response rate (RR), safety, radiologic progression-free survival (rPFS), and time to first symptomatic skeletal event (SSE) in men with mCRPC and bone metastases receiving radium-223 with/without abiraterone/prednisone or enzalu2021-01-01T00:00:00Z2021 Apr2026-05-02T14:40:14.868Z2025-04-03T21:33:42.811ZS-EPMC79853943374481210.1016/j.esmoop.2021.100082